Skip to main content
Top
Published in: Annals of Surgical Oncology 2/2018

01-02-2018 | Melanomas

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update

Authors: Sandra L. Wong, MD, Mark B. Faries, MD, Erin B. Kennedy, MHSc, Sanjiv S. Agarwala, MD, Timothy J. Akhurst, MD, Charlotte Ariyan, MD, Charles M. Balch, MD, Barry S. Berman, MD, MS, Alistair Cochran, MD, Keith A. Delman, MD, Mark Gorman, John M. Kirkwood, MD, Marc D. Moncrieff, MD, PhD, FRCS(Plast.), Jonathan S. Zager, MD, Gary H. Lyman, MD

Published in: Annals of Surgical Oncology | Issue 2/2018

Login to get access

Abstract

Purpose

To update the American Society of Clinical Oncology (ASCO)-Society of Surgical Oncology (SSO) guideline for sentinel lymph node (SLN) biopsy in melanoma.

Methods

An ASCO-SSO panel was formed, and a systematic review of the literature was conducted regarding SLN biopsy and completion lymph node dissection (CLND) after a positive sentinel node in patients with melanoma.

Results

Nine new observational studies, two systematic reviews and an updated randomized controlled trial (RCT) of SLN biopsy, as well as two randomized controlled trials of CLND after positive SLN biopsy, were included.

Recommendations

Routine SLN biopsy is not recommended for patients with thin melanomas that are T1a (non-ulcerated lesions < 0.8 mm in Breslow thickness). SLN biopsy may be considered for thin melanomas that are T1b (0.8 to 1.0 mm Breslow thickness or <0.8 mm Breslow thickness with ulceration) after a thorough discussion with the patient of the potential benefits and risk of harms associated with the procedure. SLN biopsy is recommended for patients with intermediate-thickness melanomas (T2 or T3; Breslow thickness of >1.0 to 4.0 mm). SLN biopsy may be recommended for patients with thick melanomas (T4; > 4.0 mm in Breslow thickness), after a discussion of the potential benefits and risks of harm. In the case of a positive SLN biopsy, CLND or careful observation are options for patients with low-risk micrometastatic disease, with due consideration of clinicopathological factors. For higher risk patients, careful observation may be considered only after a thorough discussion with patients about the potential risks and benefits of foregoing CLND. Important qualifying statements outlining relevant clinicopathological factors, and details of the reference patient populations are included within the guideline.
Appendix
Available only for authorised users
Literature
23.
go back to reference The Cochrane Collaboration: Part 12.2 Assessing the quality of a body of evidence, in Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, March 2011. http://handbook-5-1.cochrane.org/ The Cochrane Collaboration: Part 12.2 Assessing the quality of a body of evidence, in Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, March 2011. http://​handbook-5-1.​cochrane.​org/​
24.
go back to reference Kyrgidis A, Tzellos T, Mocellin S, et al: Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma. Cochrane Database Syst Rev. 5:CD010307, 2015. Kyrgidis A, Tzellos T, Mocellin S, et al: Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma. Cochrane Database Syst Rev. 5:CD010307, 2015.
29.
go back to reference Cigna E, Gradilone A, Ribuffo D, et al: Morbidity of selective lymph node biopsy for melanoma: meta-analysis of complications. Tumori. 98:94-98, 2012 Cigna E, Gradilone A, Ribuffo D, et al: Morbidity of selective lymph node biopsy for melanoma: meta-analysis of complications. Tumori. 98:94-98, 2012
33.
go back to reference Kingham TP, Panageas KS, Ariyan CE, et al: Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. Ann Surg Oncol. 17:514-520, 2010CrossRefPubMedPubMedCentral Kingham TP, Panageas KS, Ariyan CE, et al: Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. Ann Surg Oncol. 17:514-520, 2010CrossRefPubMedPubMedCentral
34.
36.
go back to reference Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, The Commonwealth Fund, 2008 Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, The Commonwealth Fund, 2008
44.
go back to reference Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology consensus guideline. J Clin Oncol. 35:3618-3632, 2017CrossRefPubMed Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology consensus guideline. J Clin Oncol. 35:3618-3632, 2017CrossRefPubMed
Metadata
Title
Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update
Authors
Sandra L. Wong, MD
Mark B. Faries, MD
Erin B. Kennedy, MHSc
Sanjiv S. Agarwala, MD
Timothy J. Akhurst, MD
Charlotte Ariyan, MD
Charles M. Balch, MD
Barry S. Berman, MD, MS
Alistair Cochran, MD
Keith A. Delman, MD
Mark Gorman
John M. Kirkwood, MD
Marc D. Moncrieff, MD, PhD, FRCS(Plast.)
Jonathan S. Zager, MD
Gary H. Lyman, MD
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 2/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6267-7

Other articles of this Issue 2/2018

Annals of Surgical Oncology 2/2018 Go to the issue